Levetiracetam Tecnigen (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, modulating neurotransmitter release and stabilising neuronal firing. This reduces abnormal excitability in the brain, helping to prevent the spread of seizure activity.

The dosage of Levetiracetam Tecnigen is individualized by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. The prescriber determines the appropriate starting dose and any subsequent adjustments.

The safety of levetiracetam in pregnancy and lactation has not been fully established. Healthcare providers should weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which often results in fewer drug‑drug interactions compared with enzyme‑inducing agents such as carbamazepine or phenytoin. It is generally well tolerated, but clinicians should still assess individual patient response and side‑effect profiles.

Levetiracetam Tecnigen tablets should be stored at ambient temperature below 25 °C, protected from moisture and kept in the original container to maintain stability throughout its shelf life.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with water and not crushed or chewed unless specifically advised.

Serious risks include severe allergic reactions, skin conditions such as Stevens‑Johnson syndrome, and neuropsychiatric events like suicidal thoughts, severe depression, or aggressive behavior. Patients should seek immediate medical attention if any of these occur.

Patients with known hypersensitivity to levetiracetam or any of its excipients should avoid the product. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting enzyme‑inducing antiepileptics without appropriate monitoring.